Subscription Required

Only paid subscribers* to Drug Benefit News can access this Web portal with three years of back issues, searchable article archives and other valuable resources.

Subscribers to Drug Benefit News receive

  • 24 biweekly issues of timely news and insightful strategies for reducing costs and improving outcomes, delivered by First Class U.S. Mail and electronically,
  • E-News Alerts whenever important news breaks, and
  • Access to a subscriber-only Web page with:
    • Searchable archives of past articles,
    • Convenient library with PDFs of back issues,
    • Recent stories of interest and hot topic articles grouped for convenient reading, and
    • Regular postings from your editor.
View a sample and get more information
July 29, 2016

Recent Stories

From Drug Benefit News - Adding to its growing roster of pay-for-performance deals, Harvard Pilgrim Health Care, Inc. has reached agreements with Novartis and Eli Lilly & Co. to evaluate the effectiveness of the drugmakers’ respective heart failure and diabetes drugs. The new deals reflect a growing interest in and momentum for striking performance-based risk-sharing agreements with manufacturers, although new research suggests such interest is greatest in specialty categories like hepatitis C and cancer. Read more

When the Food and Drug Administration Modernization Act (FDAMA) was enacted in… Read more

If Congress moves forward with recommendations from the latest Medicare Payment Advisory… Read more

Providers are targeting specialty pharmacy as a way to break into the… Read more

From the Editor

Welcome to your Drug Benefit News subscriber-only Web page

Be sure to visit often, for PDFs of issues, archives of articles and data, and more!

Please e-mail me with comments on the last issue of Drug Benefit News, story ideas for future issues or any other suggestions you have that can make the newsletter more useful for you.

July 1, 2016
Anthem, Express Scripts Face Consumer Lawsuit Over Drug Prices

The battle between Anthem and Express Scripts took a new turn when consumers filed a class-action lawsuit over high drug prices.

June 29, 2016
Report Finds Many Drug Prices Increased at Double the Rate of Inflation

A Bloomberg analysis found that 30 of 39 major prescription drug prices rose at double the rate of inflation from 2009-2015, even after discounts.

June 28, 2016
FDA OKs Another Gilead Hep C Therapy

The FDA approved the new Gilead drug Epclusa, the first product indicated to treat all six main genotypes of hepatitis C. Cost for 12 weeks reportedly is $74,000

Updated Regularly

Featured Hot Topics

Search for your own Hot Topics

It's quick and easy to sign up for FREE access to AISHealth.com!

Why do I need to register?